A Study to Evaluate the Efficacy of Microlyte Matrix in the Management of Donor Site Wounds

Wounds and Injuries Clinical Trial

Official title:

Clinical Trial to Assess the Efficacy of Microlyte Matrix on the Healing of Surgically Created Partial Thickness Donor Site Wounds on Patients Requiring Split-thickness Skin Grafting

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05439746
• Other study ID #: Imbed 01
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2023
• Est. completion date: January 30, 2024

Study information

• Verified date: October 2022
• Source: Imbed Biosciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A study to to evaluate the efficacy of Microlyte® Matrix by demonstrating its superiority to the standard of care in the healing of donor site wounds in patients requiring split-thickness grafting, as well as to assess the occurrence of donor site wound infection, allergic reaction, pain and itching, and scarring at 12 weeks, assessed by patients using the Patient and Observer Scar Assessment Scale (POSAS).

Description:

The proposed study is a randomized, controlled, open-label clinical trial to assess the efficacy in wound healing of the FDA 510k cleared Microlyte® Matrix (K153756) in surgically created partial thickness donor site wounds > 100 cm2 in size on patients and harvested at 12/1000th inch requiring split-thickness skin grafting. Subjects are expected to be hospitalized as in-patients for approximately 7 days following initial donor site surgery. Study visits conducted after hospital discharge must be conducted as out-patient clinic visits.

Each wound will be divided into proximal and distal halves with one half randomized to receive Microlyte® Matrix. Kaltostat/Tegaderm will be used as the control. Thus, each patient is their own control removing the potential variability of the depth of donor site wounds between patients as a confounding factor.

Microlyte® Matrix is a FDA-cleared (K153756) antimicrobial dressing manufactured by Imbed Biosciences, Inc. (Madison, WI), which is an ISO 13485 certified/FDA QSR compliant facility. It is indicated for the management of partial and full thickness wounds including pressure ulcers, venous stasis ulcers, diabetic foot ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 53
• Est. completion date: January 30, 2024
• Est. primary completion date: January 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Adult patients where creation of a donor site wound for any indication including chronic wound, burn wound, surgical/traumatic wound, and tumor excision.

2. Donor site wound with a surface area of greater than 100 cm2 is required.

3. At least 18 years of age

4. Provision of signed and dated informed consent form

5. Stated willingness to comply with all study procedures and availability for the duration of the study

6. Ability and willingness to adhere to the study intervention regimen and follow-up visits

Exclusion Criteria:

1. Age less than 18 years.

2. Vulnerable population.

3. Pregnant, lactating or nursing women.

4. Unable to provide consent.

5. Presumed unable to complete follow-up assessments.

6. Prior adverse reaction or sensitivity to silver.

7. Enrollment in another interventional trial using a systemic therapeutic within 30 days prior to enrollment for this study.

8. Presumed impairment of wound healing as with prescription drugs or medical diagnoses that have potential to impair wound healing at the discretion of clinical investigator, e.g., cancer, transplant status, autoimmune disease, severe malnutrition, etc.

9. Any diagnosis with concern for 30 Day mortality.

Related Conditions & MeSH terms

• Wounds and Injuries

Intervention

Device:
• Microlyte® Matrix
Microlyte® Matrix is indicated for the management of wounds and can be used over-the-counter for minor wounds such as abrasions and lacerations, minor cuts, and minor scalds and burns. Under the direction of a healthcare professional, Microlyte® Matrix may be used for more serious wounds such as partial and full thickness pressure ulcers, venous stasis ulcers, diabetic ulcers, first and second-degree burns, abrasions and lacerations, donor sites and surgical wounds. Microlyte® Matrix may be used over debrided and grafted partial thickness wounds.

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Imbed Biosciences	Arizona Burn Center, Maricopa Medical Center (Phoenix, AZ)

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of donor site wound closure	Therefore, assessment of the percentage wound closure at the time of primary outcome assessment (14 days) provides a very reliable method for detection of differences between groups. Digital photography and Image-J analysis allow for blinded assessment of primary outcome.	Day 14 post-op
Secondary	Percentage of donor site wound closure	Signs of infection or allergic reactions, pain, and pruritus assessed during each study visit.	Day 7 post-op
Secondary	Durability of wound closure, assessed by percentage of wound closure	Wound Closure ranges from 0%-100% with 0% being no wound closure occurring and 100% being full closure	12 weeks
Secondary	Pain, itching, and scarring, assessed by patients using the Patient and Observer Scar Assessment Scale (POSAS).	POSAS Scale is a series of questions with answers ranging from 1-10, with 1 dictating few or negligible differences from normal skin, and 10 being unimaginable scar difference from normal skin.	12 weeks
Secondary	Signs of infection or allergic reactions, pain, and pruritus		12 weeks